Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

Rezolute Inc. (NASDAQ:RZLT) is one of the top long-term biotechnology stocks to buy. Wedbush analyst Yun Zhong reaffirmed a Buy rating on Rezolute Inc. (NASDAQ:RZLT) stock on October 23, citing strong confidence in the company’s lead candidate, ersodetug.

Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

White medicinal tablets. Photo by Kaboompics.com

Currently in Phase 3 trials for congenital hyperinsulinism (cHI), the drug has shown promise in addressing a significant unmet need through its novel insulin receptor-blocking mechanism. Zhong also highlighted Rezolute’s favorable competitive position, with ersodetug poised to gain substantial market share if approved. Additional opportunities in related conditions, such as tumor-induced hypoglycemia, further support a positive long-term outlook for the company.

Rezolute Inc. (NASDAQ:RZLT) is a biopharmaceutical company that develops therapies for rare and metabolic diseases. Its primary focus is on creating treatments for hyperinsulinism (HI), a rare genetic disorder that can cause dangerously low blood sugar, with its lead candidate being ersodetug.

While we acknowledge the potential of RZLT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RZLT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.